Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs. read more
Dean Ferrigno CPA ā VP of Finance & Chief Accounting Officer at Sorrento Therapeutics
Executive Bio
Mr. Dean Ferrigno, CPA, has been VP of Finance & Chief Accounting Officer of Sorrento Therapeutics, Inc. since September 14, 2017 and May 2017 respectively. Mr. Ferrigno leads the Accounting & Finance group at Sorrento Therapeutics. Mr. Ferrigno joined Sorrento through the acquisition of Scilex Pharmaceuticals, Inc, where he served as Vice President of Finance from December 10, 2015 to 2016. He has spent the last 15 years working in pharmaceutical and research companies in senior financial roles including the Cancer Trials Network of Texas (CTNet) as Vice President of Finance and the Sarah Cannon Research Institute in 2010 as Chief Financial Officer. Prior to that, he was Senior Director of Finance with Daiichi Sankyo Research & Development. Mr. Ferrigno is a licensed CPA and holds an MBA in Corporate Finance from Fairleigh Dickinson University.
Executive Team Culture Ratings from Sorrento Therapeutics Employees
BOTTOM
45%
Sorrento Therapeutics' Executive Team scores in the Bottom 45%
of similar sized companies on Comparably
of similar sized companies on Comparably
Not Enough Ratings To Show Who Ranks Executive Team the Highest
Anonymously rate my experience at Sorrento TherapeuticsNot Enough Ratings To Show Who Ranks Executive Team the Lowest
Anonymously rate my experience at Sorrento TherapeuticsSorrento Therapeutics' Executive Team at a Glance
Based on 9 ratings, Sorrento Therapeutics' employees are less satisfied with their Executive Team and give them a āCā or 69/100.
Sorrento Therapeutics' Executive Team ranks in the Top 50% of other companies in San Diego and Bottom 45% of other companies on Comparably that also have 51-200 Employees.
×